GR3036736T3 - Osteogenesis promoter and osteoporosis remedy - Google Patents

Osteogenesis promoter and osteoporosis remedy

Info

Publication number
GR3036736T3
GR3036736T3 GR20010401593T GR20010401593T GR3036736T3 GR 3036736 T3 GR3036736 T3 GR 3036736T3 GR 20010401593 T GR20010401593 T GR 20010401593T GR 20010401593 T GR20010401593 T GR 20010401593T GR 3036736 T3 GR3036736 T3 GR 3036736T3
Authority
GR
Greece
Prior art keywords
osteogenesis
osteogenesis promoter
osteoporosis
treating
morbid condition
Prior art date
Application number
GR20010401593T
Other languages
English (en)
Inventor
Yasuo Suzuki
Yutaka Mizushima
Original Assignee
Ltt Inst Co Ltd
Kowa Co
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltt Inst Co Ltd, Kowa Co, Teijin Ltd filed Critical Ltt Inst Co Ltd
Publication of GR3036736T3 publication Critical patent/GR3036736T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GR20010401593T 1993-05-18 2001-09-27 Osteogenesis promoter and osteoporosis remedy GR3036736T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14969393 1993-05-18
PCT/JP1994/000798 WO1994026768A1 (en) 1993-05-18 1994-05-18 Osteogenesis promoter and osteoporosis remedy

Publications (1)

Publication Number Publication Date
GR3036736T3 true GR3036736T3 (en) 2001-12-31

Family

ID=15480752

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010401593T GR3036736T3 (en) 1993-05-18 2001-09-27 Osteogenesis promoter and osteoporosis remedy

Country Status (11)

Country Link
US (1) US5565444A (el)
EP (1) EP0698612B1 (el)
JP (1) JP3197562B2 (el)
AT (1) ATE203544T1 (el)
AU (1) AU6657894A (el)
CA (1) CA2162604C (el)
DE (1) DE69427815T2 (el)
ES (1) ES2163439T3 (el)
GR (1) GR3036736T3 (el)
PT (1) PT698612E (el)
WO (1) WO1994026768A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US6579936B1 (en) 1998-07-30 2003-06-17 Dainippon Ink And Chemicals, Inc. Composition of polyarylenesulfide, epoxy resin and oxazoline polymer
CA2346695A1 (en) * 1998-10-07 2000-04-13 The Board Of Trustees Of The University Of Arkansas Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof
AU1525700A (en) 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
JP4490689B2 (ja) * 2001-10-03 2010-06-30 メルク・シャープ・エンド・ドーム・コーポレイション アンドロゲン受容体調節剤としてのアンドロスタン１７β−カルボキサミド類
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
GB0523550D0 (en) * 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3271426A (en) * 1963-06-28 1966-09-06 Schering Corp Novel androstane oximino ethers and methods for their manufacture
US3741990A (en) * 1969-07-28 1973-06-26 Upjohn Co Organic compounds and processes
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents

Also Published As

Publication number Publication date
EP0698612A1 (en) 1996-02-28
PT698612E (pt) 2001-11-30
US5565444A (en) 1996-10-15
ES2163439T3 (es) 2002-02-01
CA2162604C (en) 2002-09-17
EP0698612A4 (en) 1998-05-27
AU6657894A (en) 1994-12-12
CA2162604A1 (en) 1994-11-24
EP0698612B1 (en) 2001-07-25
DE69427815D1 (de) 2001-08-30
ATE203544T1 (de) 2001-08-15
WO1994026768A1 (en) 1994-11-24
DE69427815T2 (de) 2001-11-08
JP3197562B2 (ja) 2001-08-13

Similar Documents

Publication Publication Date Title
ZA899671B (en) Phosphinic acid substituted steroids as inhibitors of steroid 5-alpha-reductase
CA2234469A1 (en) Use of an encapsulated bioactive composition
ZA899674B (en) Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-alpha-reductase
ZA899672B (en) Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-1-reductase
ATE170363T1 (de) Desinfektionsmittel
AU624405B2 (en) Heterocyclic bisphosphonic acid derivatives
SI1169337T1 (en) Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction
GR3036736T3 (en) Osteogenesis promoter and osteoporosis remedy
BG101655A (en) Composition for crop protection
NO961294L (no) Anordning for aktiv bestanddel
ZA899670B (en) Phosphonic acid substituted steroids as steroid 5-alpha-reductase inhibitors
GR3030185T3 (en) An equilin double bond isomer from the acid isomerization of equilin
WO1992019211A3 (en) Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
TW223016B (el)
DE69418744T2 (de) Verwendung von Pregnanderivaten zur Behandlung von Tumoren
HUT51288A (en) Process for production of derivatives of 19-substituated progesteron and medical compositions containing them
DE69115745D1 (de) Verwendung von Steroidderivaten zur Behandlung der Endometriose
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
IL86846A (en) Pharmaceutical compositions for preventing and treating heart failure containing indane or naphthalene carboxylic acids
ES8603457A1 (es) Procedimiento de preparacion de polimetileno iminas disustituidas
NZ237758A (en) (phenylalkyl) triphenylphosphonium salt derivatives and fungicidal compositions
EP0409999A4 (en) Liquid preparation for intraocular perfusion
MX9701010A (es) Un preventivo y un remedio para herida y/o inflamacion oftalmica.
GR1002835B (el) Χρηση παραγωγων ενωσεων μηλονικου οξεος για την επιβραδυνση της φυτικης αυξησεως.
HU9401159D0 (en) New compound leustroducsin h, its preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees